Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
1. A protein encoded by a nucleic acid comprising a start codon operatively linked to a sequence encoding a soluble CD83 protein of CD83 family of proteins selected from the group consisting of:
i) a soluble CD83 protein consisting of amino acid residues 20 to 144 of SEQ ID NO:2; and
ii) a soluble CD83 protein consisting of amino acid residues 20 to 145 of SEQ ID NO:2;
wherein in each of i) and ii) the third or fifth cysteine residue is substituted with an amino acid residue selected from the group consisting of serine, alanine, glycine, valine, threonine, aspartic acid, glutamic acid, arginine, lysine, asparagine, and glutamine; wherein said third cysteine residue corresponds to residue 100 of SEQ ID NO:2, and wherein said fifth cysteine residue corresponds to residue 129 of SEQ ID NO:2.
2. The protein of claim 1 , wherein said soluble CD83 protein consists of amino acid residues 20 to 145 of SEQ ID NO:2, and wherein the third cysteine residue of said encoded soluble CD83 protein, corresponding to residue 100 of SEQ ID NO:2, is substituted with a serine residue.
3. The protein of claim 2 that is a monomeric soluble CD83 protein.
4. A pharmaceutical composition comprising the protein of claim 3 .
5. The protein of claim 3 , wherein the protein has a native glycosylation pattern.
6. The protein of claim 3 , wherein the protein is non-glycosylated.
7. The protein of claim 1 , wherein said soluble CD83 protein consists of amino acid residues 20 to 145 of SEQ ID NO:2, and wherein the fifth cysteine residue of said encoded soluble CD83 protein, corresponding to residue 129 of SEQ ID NO:2, is substituted with a serine residue.
8. A pharmaceutical composition comprising the protein of claim 7 .
9. The protein of claim 8 , wherein the protein has a native glycosylation pattern.
10. The protein of claim 8 , wherein the protein is non-glycosylated.